Abstract:Transformed cells rely on both lipid internalization and the mobilization of intracellular lipid reservoirs, through several mechanisms such as de novo lipid biosynthesis, the mobilization of lipid droplets (LDs), and membrane remodeling. Additionally, lipid mediators, such as prostaglandin E2, cholesterol, and fatty acids derived from either the stroma or the tumor tissue, may facilitate the recruitment of non-malignant host cells, including immune cells and CAFs.Despite the complexity involved, these aspects underscore the necessity of a deeper understanding of the functions that the different lipid molecules and their metabolism play in cancer development, as well as in its progression and resistance to therapies.In this research topic "Lipid Alterations in Cancer Development, Resistance and Recurrence", the study of Gu X. et al. (Doi.org/10.3389/fcell.2022.883059) aimed to determine the effects of lipid metabolism on the progression and development of hepatocellular carcinoma (HCC). The authors used the expression profiles and clinical data of 371 and 231 patients with HCC obtained from the TCGA and Internal Cancer Genome Consortium (ICGC) databases, respectively. Through Cox and LASSO regression analyses, a prognostic risk model was constructed based on the lipid metabolism-associated genes (LMAG) data. The tumor mutation burden (TMB), immune cell infiltration levels, and immune response checkpoints of the identified risk groups were determined and compared. A total of two clusters were identified based on the LMAG expression, showing significant differences in tumor stage and immune cell infiltration. A prognostic risk model based on four LMAGs was constructed and proven to have a significant prognostic value. The 1-, 3-, and 5-year survival rates in the high-risk group were 62.2%, 20.5%, and 8.1%, respectively, whereas those in the low-risk group were 78.9%, 28.1%, and 13.5%, respectively. The survival differences between the two risk groups were likely associated with TP53 mutation status, TMB score, degree of immunocyte infiltration, and immune checkpoint level. Likewise, the expression level of every LMAG included in the model had the same effect on the overall survival and immune cell infiltration levels. More importantly, the prognostic value of the signature was verified in an independent ICGC cohort. Thus, the expression levels of LMAGs are closely related to the tumor microenvironment in HCC and may serve as promising biological indicators for prognosis and immune therapy in patients with HCC.Interestingly, the review written by Maurotti S. et al. (Doi.org/10.3389/fcell.2024.1404006) focuses on the role of the LDs in the hepatocarcinoma development. This is of particular importance because, contrary to what believed until some years ago, LDs are now considered a "metabolic hallmark" within many solid tumors like colon, prostate, breast, lung and even neurological tumors. In this review, the authors try to elucidate the LD function in all pre-tumoral stages, including Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Metabolic dysfunction-Associated Steatohepatitis (MASH), and fibrosis, which ultimately contribute to the actual development of the tumor. Some of the most important genetic alterations, as PNPLA3, TM6SF2, MBOAT7, SUGP1, MARC1, and GCKR, responsible for the different pathological liver stages are also examined. (CPTAC,n = 115) to explore the interplay between lipid metabolism and High Mobility Group Box 1 protein (HMGB1) in non-small cell lung cancer (NSCLC) tumors. Previous researches have indicated that unsaturated fatty acids can influence the expression of proteins that play a role in tumorigenesis. Here, the study is focused on specific proteins within the lipogenic and HMGB1/RAGE signaling pathways. The results demonstrated a correlation between stearoyl-CoA desaturase 1 (SCD1) and HMGB1 protein levels in NSCLC tumors. Additionally, in vitro experiments revealed that modulating SCD1 activity resulted in alterations in HMGB1 release, which was associated with changes in PD-L1 expression on the surfaces of lung cancer and innate immune cells. Preliminary analyses of select NSCLC patient samples indicated a potential association between serum HMGB1 levels and tumor-associated PD-L1 expression.In order to discover new strategies of treating cancer, it is necessary to develop a profound knowledge of the mechanisms through which disrupted lipid metabolism impacts the processes of cancer progression. It is clear that targeting a pathway or only a single-step of lipid metabolism will be probably insufficient in an attempt to develop more efficient cancer therapies. Combinatorial therapeutic approaches aimed at inhibiting tumor growth while enhancing the capacity of the immune system to target cancer cells seem to offer promising opportunities in the pharmacological research of lipid-based agents. However, there is cu -Abstract Truncated-

Identification of pre‐diagnostic lipid sets associated with liver cancer risk using untargeted lipidomics and chemical set analysis: A nested case‐control study within the ATBC cohort

Upregulation of lipid metabolism genes in the breast prior to cancer diagnosis

Lipidomic Profiles of Plasma Exosomes Identify Candidate Biomarkers for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis

Prediagnostic plasma metabolite concentrations and liver cancer risk: a population-based study of Chinese men

Proteogenomic Analysis Identifies a Causal Association Between Plasma Apolipoprotein B Levels and Liver Cancer Risk.

Comprehensive Serum Lipidomic Analyses Reveal Potential Biomarkers for Malignant Breast Cancer: A Case-Control Study.

Abstract A017: Lipidomic biomarkers of usual alcohol use and their association with pancreatic ductal adenocarcinoma risk

Higher plasma levels of lysophosphatidylcholine 18:0 are related to a lower risk of common cancers in a prospective metabolomics study

Editorial: Lipid alterations in cancer development, resistance and recurrence

Aberrant Lipid Metabolism In Hepatocellular Carcinoma Revealed By Liver Lipidomics

Comprehensive profiling of lipid metabolic reprogramming expands precision medicine for HCC

Abstract 3427: Serum metabolites and pancreatic ductal adenocarcinoma in two prospective cohorts

Pan-cancer analysis of pre-diagnostic blood metabolite concentrations in the European Prospective Investigation into Cancer and Nutrition

Metabolic perturbations prior to hepatocellular carcinoma diagnosis: Findings from a prospective observational cohort study

Reprogramming of lipid metabolism in hepatocellular carcinoma resulting in downregulation of phosphatidylcholines used as potential markers for diagnosis and prediction

Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease

Lipids, cholesterols, statins and liver cancer: a Mendelian randomization study

Untargeted plasma metabolomics and risk of colorectal cancer-an analysis nested within a large-scale prospective cohort

Differences in Prediagnostic Serum Metabolomic and Lipidomic Profiles Between Cirrhosis Patients with and without Incident Hepatocellular Carcinoma

Integrated Metabolite and Gene Expression Profiles Identify Lipid Biomarkers Associated with Progression of Hepatocellular Carcinoma and Patient Outcomes

Metabolomics biomarkers of hepatocellular carcinoma in a prospective cohort of patients with cirrhosis